• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Intarcia, Numab log milestones for autoimmune drug-device combo

June 2, 2016 By Brad Perriello

Intarcia, NumabIntarcia Therapeutics and pharmaceuticals maker Numab said today that they’ve logged several milestones in their joint project to develop a drug-device combination for treating inflammatory and autoimmune diseases.

Wädenswil, Switzerland-based Numab identified a pair of antibody-based compounds for the program, which aims to use the delivery and formulation technology developed by Cambridge, Mass.-based Intarcia.

The companies said Intarcia has successfully formulated versions of both the molecule targets identified by Numab.

“Achievement of this milestone for Intarcia further confirms the power of Numab’s discovery platform to produce next-generation antibody-based therapeutics, as well as our commitment to exceed expectations with our strategic partners,” Numab co-CEO David Urech said in prepared remarks.

“Our Numab collaboration continues to progress with cutting-edge science and technologies capable of delivering important new medicines and combinations in our therapeutic areas of focus. The progress brings us 1 step closer to delivering very promising and important new once or twice-yearly medicines in large and serious chronic diseases where we are uniquely positioned to address unmet needs,” added Intarcia chairman, president & CEO Kurt Graves.

Filed Under: Discovery, Drug-Device Combinations Tagged With: Intarcia Therapeutics, Numab

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS